The drug is a joint venture between Bayer Healthcare Pharmaceuticals and Johnson & Johnson. Johnson & Johnson has applied for approval for short-term use of the drug in the prevention of deep-vein thrombosis and pulmonary embolism in patients undergoing total hip and knee replacement surgery.
The company has recently finished clinical trials on the longer-term use of rivaroxaban in patients with acute coronary syndrome.
Read about the FDA panel’s recommendation to approve rivaroxaban.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
